Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery

Journal of Gastroenterology

Volumn 51, Issue 3, 2016, Pages 281-289

  Seki, Yosuke ^a   Kakizaki, Satoru ^b   Horiguchi, Norio ^b   Hashizume, Hiroaki ^b   Tojima, Hiroki ^b   Yamazaki, Yuichi ^b   Sato, Ken ^b   Kusano, Motoyasu ^b   Yamada, Masanobu ^b   Kasama, Kazunori ^a  

^a Yotsuya Medical Cube   (Japan)

^b GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bariatric surgery; Morbidly obesity; Nonalcoholic steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BARIATRIC SURGERY; BODY MASS; BODY WEIGHT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; JAPANESE (PEOPLE); LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; THROMBOCYTE COUNT; TREATMENT INDICATION; WAIST HIP RATIO; ANTHROPOMETRY; COMPLICATION; JAPAN; LIVER; MIDDLE AGED; NEEDLE BIOPSY; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; ANTHROPOMETRY; BARIATRIC SURGERY; BIOPSY, NEEDLE; FEMALE; HUMANS; INSULIN RESISTANCE; JAPAN; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84959075912     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-015-1114-8     Document Type: Article

References (42)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA. 2002;288:1723–7.
2. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122:1649–57.
3. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;8:960–77.
4. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124:71–9.
5. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.
6. Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91–100.
7. Chisholm J, Seki Y, Toouli J, Stahl J, Collins J, Kow L. Serologic predictors of nonalcoholic steatohepatitis in a population undergoing bariatric surgery. Surg Obes Relat Dis. 2012;8:416–22.
8. Crespo J, Fernandez-Gil P, Hernandez-Guerra M, et al. Are there predictive factors of severe liver fibrosis in morbidly obese patients with nonalcoholic steatohepatitis? Obes Surg. 2001;11:254–7.
9. Stratopoulos C, Papakonstantinou A, Terzis I, et al. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity. Obes Surg. 2005;15:1154–60.
10. Harnois F, Msika S, Sabaté JM, et al. Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2006;16:183–8.
11. Gholam PM, Kotler DP, Flancbaum LJ. Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg. 2002;12:49–51.
12. Beymer C, Kowdley KV, Larson A, et al. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg. 2003;138:1240–4.
13. Spaulding L, Trainer T, Janiec D. Prevalence of nonalcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass. Obes Surg. 2003;13:347–9.
14. Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology. 2004;40:475–83.
15. Shalhub S, Parsee A, Gallagher SF, et al. The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients. Obes Surg. 2004;14:54–9.
16. Ong JP, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005;15:310–5.
17. Guajardo-Salinas GE, Hilmy A. Prevalence of nonalcoholic fatty liver disease (NAFLD) and utility of FIBROspect II to detect liver fibrosis in morbidly obese Hispano-American patients undergoing gastric bypass. Obes Surg. 2010;20:1647–53.
18. Sepúlveda-Flores RN, Vera-Cabrera L, Flores-Gutiérrez JP, et al. Obesity-related non-alcoholic steatohepatitis and TGF-β1 serum levels in relation to morbid obesity. Ann Hepatol. 2002;1:36–9.
19. Moretto M, Kupski C, Mottin CC, et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities. Obes Surg. 2003;13:622–4.
20. Lima ML, Mourão SC, Diniz MT, Leite VH. Hepatic histopathology of patients with morbid obesity submitted to gastric bypass. Obes Surg. 2005;15:661–9.
21. Boza C, Riquelme A, Ibañez L, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg. 2005;15:1148–53.
22. Liang RJ, Wang HH, Lee WJ, Liew PL, Lin JT, Wu MS. Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery. Obes Surg. 2007;17:45–56.
23. Tai CM, Huang CK, Tu HP, Hwang JC, Chang CY, Yu ML. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease. Surg Obes Relat Dis. 2015;11:888–94.
24. Praveenraj P, Gomes RM, Kumar S, et al. Prevalence and predictors of non-alcoholic fatty liver disease in morbidly obese south Indian patients undergoing bariatric surgery. Obes Surg. 2015. doi:10.1007/s11695-015-1655-1.
25. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45:600–6.
26. Yoshiike N, Matsumura Y, Zaman M, Yamaguchi M. Descriptive epidemiology of body mass index in Japanese adults in a representative sample from the national nutrition survey 1990–1994. Int J Obes Relat Metab Disord. 1998;22:684–7.
27. Ohshiro Y, Ueda K, Nishi M, et al. A polymorphic marker in the leptin gene associated with Japanese morbid obesity. J Mol Med. 2000;78:516–20.
28. Kakizaki S, Takizawa D, Yamazaki Y, et al. Nonalcoholic fatty liver disease in Japanese patients with severe obesity who received laparoscopic Roux-en-Y gastric bypass surgery (LRYGB) in comparison to non-Japanese patients. J Gastroenterol. 2008;43:86–92.
29. Lee WJ, Wang W. Bariatric surgery: Asia-Pacific perspective. Obes Surg. 2005;15:751–7.
30. The Japan Diabetes Society. Evidence-based practice guideline for the treatment for diabetes in Japan 2013. Tokyo: Nankodo; 2013.
31. Lee RG. Nonalcoholic steatohepatitis: tightening the morphological screws on a hepatic rambler. Hepatology. 1995;21:1742–3.
32. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.
33. Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference statement. Am J Clin Nutr. 1992;55:615S–9S.
34. Watanabe S, Hashimoto E, Ikejima K, et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol. 2015;50:364–77.
35. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int. 2006;26:151–6.
36. Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:34.
37. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol. 2007;102:399–408.
38. Campos GM, Bambha K, Vittinghoff E, et al. A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients. Hepatology. 2008;47:1916–23.
39. Anty R, Iannelli A, Patouraux S, et al. A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients. Aliment Pharmacol Ther. 2010;32:1315–22.
40. Sumida Y, Yoneda M, Hyogo H, et al. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:257–68.
41. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22:222–6.
42. Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39:1647–54.